Image

The US Food and Drug Administration (FDA) has accepted and granted priority review to AbbVie’s new drug application for its interferon-free regimen to treat adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

In April, AbbVie submitted the new drug application to the FDA for its investigational, all-oral, interferon-free therapy for the treatment of GT1 HCV.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The submission is supported by data from a large clinical programme, including six Phase III studies of more than 2,300 GT1 patients in at least 25 countries.

The multi-centre studies include PEARL-II, PEARL-III, PEARL-IV, TURQUOISE-II, SAPPHIRE-I and SAPPHIRE-II.

"The submission is supported by data from a large clinical programme, including six Phase III studies of more than 2,300 GT1 patients in at least 25 countries."

In May 2013, the FDA had granted a breakthrough therapy designation for the interferon-free regimen. AbbVie submitted marketing authorisation applications for regulatory approval in the EU in May 2014.

The three direct-acting antiviral investigational regimen consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once-daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed twice-daily.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ABT-450 is Enanta Pharmaceuticals’ lead protease inhibitor developed through its collaboration with AbbVie. AbbVie is developing ABT-450 for use in combination with its other investigational medicines for the treatment of hepatitis C.

According to AbbVie, the combination of three different mechanisms of action interrupts the hepatitis C virus replication process with the goal of optimising sustained virologic response rates across different patient populations.

Image: 3D rendering of an hepatitis virus in digital background. Photo: courtesy of freedigitalphotos.net.